initial public offerings (IPOs) trading on American exchanges

Monday, March 17, 2014

Five Prime Therapeutics (FPRX) began trading on the NASDAQ on 18 September 2013

3/17/2014 chart update (daily)


Five Prime Therapeutics, Inc. is a clinical-stage biotechnology company focused on discovering and developing protein therapeutics. Protein therapeutics is antibodies or drugs developed from extracellular proteins or protein fragments that block disease processes, including cancer and inflammatory diseases. The Company’s advanced product candidates include FP-1039/GSK3052230 (FP-1039), FPA008 and FPA144. FP-1039 is a protein therapeutic that traps and neutralizes cancer-promoting fibroblast growth factors (FGFs), involved in cancer cell proliferation and new blood vessel formation. FPA008 is an antibody that inhibits colony stimulating factor-1 receptor (CSF1R), and is being developed to treat patients with inflammatory diseases, including rheumatoid arthritis (RA). FPA144 is an antibody that inhibits FGF receptor 2b (FGFR2b), and is being developed to treat patients with gastric cancer and potentially other solid tumors.


Two Corporate Drive
United States 

Key stats and ratios

Q3 (Sep '13)2012
Net profit margin-207.75%-276.42%
Operating margin-210.17%-278.51%
EBITD margin--262.06%
Return on average assets-45.55%-53.75%
Return on average equity--

No comments:

Post a Comment